Zoetis is set to acquire Abaxis in a $1.9bn deal

By Catherine Sturman
Zoetis Inc. is set to acquire Abaxis, a leader in the development, manufacture and marketing of diagnostic instruments for veterinary point-of-care serv...

Zoetis Inc. is set to acquire Abaxis, a leader in the development, manufacture and marketing of diagnostic instruments for veterinary point-of-care services.

The acquisition is expected to enhance Zoetis’ presence in veterinary diagnostics, a category of the animal health industry with approximately 10% compound annual growth over the last three years.

A leader of diagnostic instruments and consumable discs, kits and cartridges to the animal health industry, Abaxis reported a revenue of $244.7mn for its fiscal year ended March 31, an increase of 8%, compared with its 2017 fiscal year.

Its VetScan portfolio of benchtop and handheld diagnostic instruments and consumables serves a large customer base of veterinary practices in North America and is poised for expansion in international markets.

“This acquisition brings Zoetis a proven, competitive diagnostic platform for growth that we can help to accelerate in the US and worldwide with our global scale and direct customer relationships in approximately 45 countries,” said Juan Ramón Alaix, Chief Executive Officer of Zoetis.

“Together, we can bring more veterinarian customers a broader range of products that fit into our comprehensive solutions and innovations, from prediction and early detection of disease in animals to prevention and treatment.”

See also

“We recently invested in expanding operations in Europe, Latin America, and the Asia Pacific Region, with 20% of revenue in fiscal year 2018 coming from our international operations,” added Clint Severson, Chairman and Chief Executive Officer of Abaxis.

“Zoetis has the global presence and direct veterinary customer relationships to deliver greater value to more customers around the world and accelerate the growth of our international operations.”

Abaxis derived 83% ($201.9mn) of its annual revenue in fiscal year 2018 from diagnostic products and services for the veterinary market. Approximately 16% ($38.6mn) of the company’s revenues were generated by sales of its Piccolo portfolio of analysers and tests for the human medical market.

  • Sales of consumables accounted for approximately 78% ($191.3mn) of Abaxis’ fiscal 2018 revenue. Abaxis has more than 580 employees worldwide.

The veterinary diagnostics category is estimated to be more than $3 billion, with compound annual growth of 10% over the past three years.

Zoetis expects to complete the acquisition by the end of 2018.


Featured Articles

TrueBinding’s antibody drugs fight Alzheimer’s Disease

Dongxu Sun, CEO at TrueBinding, shares how its research & antibody drug development is fighting illnesses such as Alzheimer’s Disease, stroke & more

Cardinal Health’s clinically integrated pharma supply chain

Peter Siavelis, SVP & General Manager, Health System and Provider Distribution & Services at Cardinal Health, discusses the integrated pharma supply chain

Healthcare Digital news roundup: digital healthcare & AI

This week in Healthcare Digital, we looked at digital skills for healthcare leaders, medical technology & acoustic AI used in digital cough monitoring

Hospitals must embrace IoMT device security


Mental health support for working women and mothers

Digital Healthcare

Digital evolution delivers better healthcare outcomes

Digital Healthcare